Elite Pharmaceuticals Inc (ELTP)

[HGiLS]

we are 54% margin average for the year so far - Jour is whining about Calm down:

Gross Margins in the Generic Pharmaceutical Industry
Gross margin, calculated as (revenue - cost of goods sold) / revenue, represents the percentage of revenue retained after accounting for direct production costs. For generic pharmaceutical companies, which produce off-patent drugs and compete primarily on price and volume, gross margins are typically lower than those of branded (innovator) drug manufacturers due to intense pricing pressure, commoditization, and thin competition. However, they remain profitable through scale, efficient manufacturing, and high-volume sales.
Typical Range
Based on industry analyses and financial data:

Gross margins for generic manufacturers generally range from 40% to 60%. This reflects their focus on cost-efficient production and distribution.
Lower end (around 40%): Common for highly competitive generics with low barriers to entry.
Higher end (up to 60%): Achieved by companies with optimized supply chains or focus on complex generics (e.g., injectables or biosimilars).

For comparison, branded pharmaceutical companies often see gross margins of 70-85%, driven by patent protections and premium pricing.

Key Data Points
Here's a summary of reported gross margins for generic drug manufacturers from recent sources:






























Source/YearReported Gross MarginNotes/ContextBCG Analysis (2019-2021)~50% for manufacturersDerived from cost of goods sold (COGS) benchmarks; internal conversion costs are ~30% of total COGS, leaving room for ~50% margin after API and procurement costs.DrugPatentWatch (2025)~40%Industry average for generic producers, including branded generics; contrasts with 80% for patent-protected drugs.Brookings Institution (2017)50%Manufacturer-specific margin on generics in the U.S. distribution chain; pharmacies see higher (43%), but manufacturers are at the lower end.ASPE Report (2022)Implied ~50-60% (wholesaler margins at $9.3B on generics)Focuses on supply chain; generic spending was lower volume but still yielded solid manufacturer margins.
Factors Influencing Margins

Pricing Dynamics: Generics face rapid erosion post-patent expiry, with prices dropping 80-90% in some cases, compressing margins.
Scale and Efficiency: Large players like Teva or Mylan (now Viatris) leverage global manufacturing to maintain 45-55% margins.
Trends: Margins have been stable but face downward pressure from regulatory scrutiny and supply chain disruptions (e.g., API shortages). Net profit margins for generics are often 10-20%, after R&D and marketing costs.

For company-specific data, margins can vary; e.g., Teva's gross margin was ~42% in recent quarters, while Dr. Reddy's hovered around 55%. If you need details on a particular company or region, provide more context!